[Novel anti-osteoporotic drugs on the horizon]

A Knauerhase1, H S Willenberg2

  • 1Zentrum für Innere Medizin, Abteilung für Gastroenterologie/Endokrinologie, Sektion Endokrinologie/Stoffwechselerkrankungen, Universitätsmedizin Rostock, E.-Heydemann-Str. 6, 18055, Rostock, Deutschland. andreas.knauerhase@uni-rostock.de.

Insights

New bone cell biology insights reveal targeted therapies. Targeting osteoclast and osteoblast pathways, like RANK-RANK-ligand (RANKL) and Wnt, can inhibit bone resorption or enhance bone formation for fracture prevention.

Area of Science:

  • Bone cell biology
  • Molecular targets in bone metabolism

Background:

  • Advances in bone cell biology have identified druggable targets for therapeutic intervention.
  • Osteoclast and osteoblast activity is regulated by specific signaling pathways, including RANK-RANK-ligand (RANKL) and Wnt.

Purpose of the Study:

  • To explore therapeutic strategies targeting bone cell biology for enhanced bone formation and inhibited resorption.
  • To discuss the implications of novel therapeutic principles in bone anabolic activity and fracture prevention.

Main Methods:

  • Targeting the RANK-RANK-ligand (RANKL) pathway to decrease osteoclast number and function.
  • Targeting the Wnt signaling pathway to increase osteoblast genesis.
  • Investigating cathepsin K inhibition to stabilize bone matrix.
  • Exploring synthetic analogues of parathyroid hormone-related protein for bone anabolic activity.

Main Results:

  • Modulating RANKL and Wnt pathways can respectively decrease osteoclasts or increase osteoblasts, leading to inhibited resorption or enhanced formation.
  • Inactivating cathepsin K stabilizes bone matrix while preserving osteoblast cross-talk, potentially avoiding reduced new bone formation.
  • Synthetic parathyroid hormone-related protein analogues show potential for potent bone anabolic activity.

Conclusions:

  • Targeted therapies offer promising approaches to modulate bone resorption and formation.
  • New therapeutic principles necessitate careful consideration of treatment sequencing, duration, long-term effects, and comparative effectiveness for fracture prevention.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.6K
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.9K
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
6.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
316
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K